Article
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
Leukemia & lymphoma - 1 Dec 2013
Jones Jeffrey A, Ruppert Amy S, Zhao Weiqiang, Lin Thomas S, Rai Kanti, Peterson Bercedis, Larson Richard A, Marcucci Guido, Heerema Nyla A, Byrd John C
Abstract excerpt
Alemtuzumab consolidation has been investigated to improve remission duration after fludarabine-based induction for chronic lymphocytic leukemia (CLL). The impact on genomic high-risk disease remains unknown. Cancer and Leukemia Group B (CALGB) 19901 and 10101 enrolled previously untreated patients to receive alemtuzumab consolidation after fludarabine-based induction. Immunoglobulin heavy chain gene (IGVH)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.